Determinants and prognostic significance of electrocardiographic left ventricular hypertrophy criteria in chronic kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 6, Issue 3, 2011, Pages 528-536

  Agarwal, Rajiv ^a,b   Light, Robert P ^a  

^a INDIANA UNIVERSITY   (United States)

^b RICHARD L ROUDEBUSH VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ANEMIA; ARTICLE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORNELL CRITERION; DIAGNOSTIC VALUE; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREVALENCE; PROGNOSIS; PROTEINURIA; SOKOLOW LYON CRITERION; SYSTOLIC BLOOD PRESSURE;

AGED; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, VETERANS; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INDIANA; KIDNEY DISEASES; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 79953003556     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.07770910     Document Type: Article

References (21)

1. Kannel WB, Gordon T, Offutt D: Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence, and mortality in the Framingham study. Ann Intern Med 71: 89-105, 1969
2. Kannel WB: Left ventricular hypertrophy as a risk factor: The Framingham experience. J Hypertens Suppl 9: S3-S8, 1991
3. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 104: 1615-1621, 2001 (Pubitemid 32947523)
4. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Wedel H, Lindholm LH, Dahlof B: Regression of electrocardiographic left ventricular hypertrophy during antihypertensive treatment and the prediction of major cardiovascular events. JAMA 292: 2343-2349, 2004 (Pubitemid 39491918)
5. Manjunath G, Sarnak MJ, Levey AS: Prediction equations to estimate glomerular filtration rate: An update. Curr Opin Nephrol Hypertens 10: 785-792, 2001 (Pubitemid 33043673)
6. Wright JT Jr, Bakris G, Greene T, Agodoa LY, Appel LJ, Charleston J, Cheek D, Douglas-Baltimore JG, Gassman J, Glassock R, Hebert L, Jamerson K, Lewis J, Phillips RA, Toto RD, Middleton JP, Rostand SG: Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial. JAMA 288: 2421-2431, 2002 (Pubitemid 35340538)
7. Agarwal R, Andersen MJ: Correlates of systolic hypertension in patients with chronic kidney disease. Hypertension 46: 514-520, 2005 (Pubitemid 41376831)
8. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 359: 995-1003, 2002 (Pubitemid 34286536)
9. Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 37: 161-186, 1949
10. Feiveson A: TRYEM: Stata Module to Run All Possible Subset Regressions, College Station, TX, Stata Press, 2006
11. Cleves MA, Gould WW, Gutierrez RG: An Introduction to Survival Analysis Using Stata, Revised Ed., College Station, TX, Stata Press, 2004
12. Rahman M, Brown CD, Coresh J, Davis BR, Eckfeldt JH, Kopyt N, Levey AS, Nwachuku C, Pressel S, Reisin E, Walworth C: The prevalence of reduced glomerular filtration rate in older hypertensive patients and its association with cardiovascular disease: A report from the Antihypertensive and Lip- id-Lowering Treatment to Prevent Heart Attack Trial. Arch Intern Med 164: 969-976, 2004 (Pubitemid 38581516)
13. Redon J, Cea-Calvo L, Lozano JV, Fernandez-Perez C, Navarro J, Bonet A, Gonzalez-Esteban J: Kidney function and cardiovascular disease in the hypertensive population: The ERIC-HTA study. J Hypertens 24: 663-669, 2006
14. Krane V, Heinrich F, Meesmann M, Olschewski M, Lilienthal J, Angermann C, Stork S, Bauersachs J, Wanner C, Frantz S: Electrocardiography and outcome in patients with diabetes mellitus on maintenance hemodialysis. Clin J Am Soc Nephrol 4: 394-400, 2009
15. Levin A, Singer J, Thompson CR, Ross H, Lewis M: Prevalent left ventricular hypertrophy in the predialysis population: Identifying opportunities for intervention. Am J Kidney Dis 27: 347-354, 1996 (Pubitemid 26075843)
16. Agarwal R, Brim NJ, Mahenthiran J, Andersen MJ, Saha C: Out-ofhemodialysis-unit blood pressure is a superior determinant of left ventricular hypertrophy. Hypertension 47: 62-68, 2006 (Pubitemid 43180109)
17. Foley RN, Parfrey PS, Harnett JD, Kent GM, Martin CJ, Murray DC, Barre PE: Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 47: 186-192, 1995
18. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Dahlof B: Baseline characteristics in relation to electrocardiographic left ventricular hypertrophy in hypertensive patients: The Losartan intervention for endpoint reduction (LIFE) in hypertension study. The Life Study Investigators. Hypertension 36: 766-773, 2000
19. Lee DK, Marantz PR, Devereux RB, Kligfield P, Alderman MH: Left ventricular hypertrophy in black and white hypertensives. Standard electrocardiographic criteria overestimate racial differences in prevalence. JAMA 267: 3294-3299, 1992
20. Levin A, Thompson CR, Ethier J, Carlisle EJ, Tobe S, Mendelssohn D, Burgess E, Jindal K, Barrett B, Singer J, Djurdjev O: Left ventricular mass index increase in early renal disease: Impact of decline in hemoglobin. Am J Kidney Dis 34: 125-134, 1999 (Pubitemid 29318806)
21. MacKinnon DP, Krull JL, Lockwood CM: Equivalence of the mediation, confounding and suppression effect. Prev Sci 1: 173-181, 2000